IMPEDE-VTE
IMPEDE‑VTE estimates the risk of venous thromboembolism in multiple myeloma patients initiating therapy.
适用指征
Identifies newly diagnosed multiple myeloma patients starting IMiD‑based therapy who need VTE risk stratification. Assists in selecting primary thromboprophylaxis by categorizing patients into low, intermediate, or high risk based on validated predictors. External validation shows moderate discrimination (c‑statistic ~0.64) and superior performance to IMWG/NCCN criteria 1 [Level II evidence].
洞见与注意事项
Stratify MM patients on IMiD‑based therapy into low, intermediate, and high VTE risk, but apply cautiously because external validation shows borderline discrimination (c‑statistic ~0.64) and need for prospective validation 1 [Level II evidence]; 2 [Level II evidence]. Insights: captures MM‑specific treatment triggers; simple to score. Cautions: risk inflation with multiple time‑varying factors, limited generalizability, and not yet guideline‑endorsed as definitive.